How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?

IF 3.4 Q2 GASTROENTEROLOGY & HEPATOLOGY

Intestinal Research Pub Date : 2023-07-01 DOI:10.5217/ir.2023.00061

Jihye Park

{"title":"How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?","authors":"Jihye Park","doi":"10.5217/ir.2023.00061","DOIUrl":null,"url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 275 gy of IBD, according to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study, from 1990 to 2019, age-standardized prevalence increased most rapidly in East Asia and high-income Asia-Pacific regions. According to the healthcare costs, van Linschoten et al. assessed the cost of illness of IBD according to each continent including Asia, Europe, North America, and Oceania from 1985 to 2018. The healthcare costs were increasing on all continents, and the cost trend is primarily attributable to an increase in medication costs. Although costs in Asia were lower than in Europe and North America, but no studies from Asia or Oceania were eligible for this analysis at that time period. In summary, it is essential to understand treatment patterns for IBD in Asian countries, because of rapid increase of IBD in Asia due to Westernization, changes in prescription patterns in the West over time, and unique characteristics between the East and the West. The organizing committee of the Asian Organization for Crohn’s and Colitis (AOCC) reported first web-based survey results for the current status of IBD management conducted by 353 Asian medical doctors from Korea, China, Japan, India, Hon Kong, Singapore, Taiwan, Malaysia, Philippines, and Indonesia in the 2nd annual AOCC meeting in 2014. For mild to moderate UC and mild to moderate Crohn’s disease (CD), 5-aminosalicylic acid treatment were common first line therapy in Asian countries. For steroid-refractory acute severe UC, most physicians selected anti-tumor necrosis factor (TNF) agents followed by cyclosporine, on the contrary, Japanese pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00061 Intest Res 2023;21(3):275-276","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/67/ir-2023-00061.PMC10397554.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intestinal Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5217/ir.2023.00061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 275 gy of IBD, according to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study, from 1990 to 2019, age-standardized prevalence increased most rapidly in East Asia and high-income Asia-Pacific regions. According to the healthcare costs, van Linschoten et al. assessed the cost of illness of IBD according to each continent including Asia, Europe, North America, and Oceania from 1985 to 2018. The healthcare costs were increasing on all continents, and the cost trend is primarily attributable to an increase in medication costs. Although costs in Asia were lower than in Europe and North America, but no studies from Asia or Oceania were eligible for this analysis at that time period. In summary, it is essential to understand treatment patterns for IBD in Asian countries, because of rapid increase of IBD in Asia due to Westernization, changes in prescription patterns in the West over time, and unique characteristics between the East and the West. The organizing committee of the Asian Organization for Crohn’s and Colitis (AOCC) reported first web-based survey results for the current status of IBD management conducted by 353 Asian medical doctors from Korea, China, Japan, India, Hon Kong, Singapore, Taiwan, Malaysia, Philippines, and Indonesia in the 2nd annual AOCC meeting in 2014. For mild to moderate UC and mild to moderate Crohn’s disease (CD), 5-aminosalicylic acid treatment were common first line therapy in Asian countries. For steroid-refractory acute severe UC, most physicians selected anti-tumor necrosis factor (TNF) agents followed by cyclosporine, on the contrary, Japanese pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00061 Intest Res 2023;21(3):275-276

查看原文本刊更多论文

亚洲国家炎症性肠病患者的治疗模式发生了怎样的变化?

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Intestinal Research GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.40

自引率

10.20%

发文量

审稿时长

38 weeks

期刊介绍： Intestinal Research (Intest Res) is the joint official publication of the Asian Organization for Crohn''s and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn''s Foundation (India) (CCF, india). The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include inflammatory bowel disease, colon and small intestine cancer or polyp, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth. The Journal publishes diverse types of academic materials such as editorials, clinical and basic reviews, original articles, case reports, letters to the editor, brief communications, perspective, statement or commentary, and images that are useful to clinicians and researchers.